The DOI matches its Crossref record; 774 of the 774 references it cites were found in a registry or an index.
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Abstract
A number of therapeutic drugs with different structures and mechanisms of action have been reported to undergo metabolic activation by Phase I or Phase II drug-metabolizing enzymes. The bioactivation gives rise to reactive metabolites/intermediates, which readily confer covalent binding to various target proteins by nucleophilic substitution and/or Schiff's base mechanism. These drugs include analgesics (e.g., acetaminophen), antibacterial agents (e.g., sulfonamides and macrolide antibiotics), anticancer drugs (e.g., irinotecan), antiepileptic drugs (e.g., carbamazepine), anti-HIV agents (e.g., ritonavir), antipsychotics (e.g., clozapine), cardiovascular drugs (e.g., procainamide and hydralazine), immunosupressants (e.g., cyclosporine A), inhalational anesthetics (e.g., halothane), nonsteroidal anti-inflammatory drugs (NSAIDSs) (e.g., diclofenac), and steroids and their receptor modulators (e.g., estrogens and tamoxifen). Some herbal and dietary constituents are also bioactivated to reactive metabolites capable of binding covalently and inactivating cytochrome P450s (CYPs). A number of important target proteins of drugs have been identified by mass spectrometric techniques and proteomic approaches. The covalent binding and formation of drug-protein adducts are generally considered to be related to drug toxicity, and selective protein covalent binding by drug metabolites may lead to selective organ toxicity. However, the mechanisms involved in the protein adduct-induced toxicity are largely undefined, although it has been suggested that drug-protein adducts may cause toxicity either through impairing physiological functions of the modified proteins or through immune-mediated mechanisms. In addition, mechanism-based inhibition of CYPs may result in toxic drug-drug interactions. The clinical consequences of drug bioactivation and covalent binding to proteins are unpredictable, depending on many factors that are associated with the administered drugs and patients. Further studies using proteomic and genomic approaches with high throughput capacity are needed to identify the protein targets of reactive drug metabolites, and to elucidate the structure-activity relationships of drug's covalent binding to proteins and their clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,665
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) · Science · doi:10.1126/science.275.5297.218 · Cited by 4,935 · cited 1×
“The irreversible inhibition of CYPs by resveratrol may be related to its antioxidant and antimutagenic properties (Jang et al., 1997); and inactivation of CYPs bioactivating procarcinogens by herbal constituents would contribute to their chemopreventive action.”
BackgroundThalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Metabonomics: a platform for studying drug toxicity and gene function
Nicholson, J. K., Connelly, J., Lindon, J. C., & Holmes, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd728 · Cited by 1,914
Hamer, D. H. (1986) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.55.070186.004405 · Cited by 1,800
Common and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity
Guengerich, F. P. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002583 · Cited by 1,655
Severe Adverse Cutaneous Reactions to Drugs
Roujeau, J. C., & Stern, R. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311906 · Cited by 1,571
Photochemotherapy of Psoriasis with Oral Methoxsalen and Longwave Ultraviolet Light
Parrish, J. A., Fitzpatrick, T. B., Tanenbaum, L., & Pathak, M. A. (1974) · New England Journal of Medicine · doi:10.1056/nejm197412052912301 · Cited by 1,376
Jaeschke, H. (2002) · Toxicological Sciences · doi:10.1093/toxsci/65.2.166 · Cited by 1,304
Fisher, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., Cronin, W. M., & Contributors, O. N. (1994) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/86.7.527 · Cited by 1,268
ACETAMINOPHEN-INDUCED HEPATIC NECROSIS. II. ROLE OF COVALENT BINDING IN VIVO
Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29664-1 · Cited by 1,204
Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal Photochemotherapy
Edelson, R., Berger, C., Gasparro, F., Jegasothy, B., Heald, P., Wintroub, B., Vonderheid, E., Knobler, R., Wolff, K., Plewig, G., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702053160603 · Cited by 1,199
Hass, W. K., Easton, J. D., Adams, H. P., Pryse-Phillips, W., Molony, B. A., Anderson, S., Kamm, B., & for the Ticlopidine Aspirin Stroke Study Group (1989) · New England Journal of Medicine · doi:10.1056/nejm198908243210804 · Cited by 1,198
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.699 · Cited by 1,192
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Mcbride, W. G. (1961) · The Lancet · doi:10.1016/s0140-6736(61)90927-8 · Cited by 1,141
(2017) · Arzneimittelforschung · doi:10.1055/s-00000175 · Cited by 1,134
Acetaminophen-induced Hepatic Necrosis
Jollow, D. J., Thorgeirsson, S. S., Potter, W. Z., Hashimoto, M., & Mitchell, J. R. (1974) · Pharmacology · doi:10.1159/000136547 · Cited by 1,092
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Role of P-Glycoprotein in Pharmacokinetics: Clinical Implications
Lin, J. H., & Yamazaki, M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342010-00003 · Cited by 998
Postmenopausal Hormone Replacement Therapy: Scientific Review
Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., & Allan, J. D. (2002) · JAMA · doi:10.1001/jama.288.7.872 · Cited by 990 · cited 1×
“Hormone replacement therapy is used in postmenopausal women to prevent osteoporotic fractures and colorectal cancer (Nelson et al., 2002).”
BackgroundClozapine-induced agranulocytosis. incidence and risk factors in the united states
Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290303 · Cited by 967
Haller, C. A., & Benowitz, N. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432502 · Cited by 956
GRAHAM, D. G., TIFFANY, S. M., BELL, W. R., & GUTKNECHT, W. F. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13536-0 · Cited by 953
Rendic, S., & Carlo, F. J. D. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709037591 · Cited by 949
The Human Hepatic Cytochromes P450 Involved in Drug Metabolism
Wrighton, S. A., & Stevens, J. C. (1992) · Critical Reviews in Toxicology · doi:10.3109/10408449209145319 · Cited by 944
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038010-00003 · Cited by 908
Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1.
Shimada, T., Hayes, C. L., Yamazaki, H., Amin, S., Hecht, S. S., Guengerich, F. P., & Sutter, T. R. (1996) · PubMed · Cited by 895
The pharmacology and clinical uses of tamoxifen
Furr, B. J. A., & Jordan, V. C. (1984) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(84)90043-3 · Cited by 864
Göttlinger, H. G., Sodroski, J. G., & Haseltine, W. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.15.5781 · Cited by 841
Glutathione-S-transferase family of enzymes
Strange, R. C., Spiteri, M. A., Ramachandran, S., & Fryer, A. A. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00206-8 · Cited by 831
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Ding, X., & Kaminsky, L. S. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140251 · Cited by 822
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
[69] Overview of metallothionein
Kägi, J. H. R. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)05145-l · Cited by 811
A Review of the Pharmacological and Clinical Profile of Mirtazapine
Anttila, S. A. K., & Leinonen, E. V. J. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00198.x · Cited by 795
Antioxidant and other biological activities of phenols from olives and olive oil
Visioli, F., Poli, A., & Gall, C. (2002) · Medicinal Research Reviews · doi:10.1002/med.1028 · Cited by 754
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Grapefruit juice–drug interactions
Bailey, D. G., Malcolm, J., Arnold, O., & David Spence, J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00764.x · Cited by 740
Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules
Miller, E. C., & Miller, J. A. (1981) · Cancer · doi:10.1002/1097-0142(19810515)47:10<2327::aid-cncr2820471003>3.0.co;2-z · Cited by 730
Bessems, J. G. M., & Vermeulen, N. P. E. (2001) · Critical Reviews in Toxicology · doi:10.1080/20014091111677 · Cited by 715
Major phenolic compounds in olive oil: metabolism and health effects
Tuck, K. L., & Hayball, P. J. (2002) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(02)00229-2 · Cited by 705
Perucca, E. (2002) · CNS Drugs · doi:10.2165/00023210-200216100-00004 · Cited by 690
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data
Lee, C. R., Goldstein, J. A., & Pieper, J. A. (2002) · Pharmacogenetics · doi:10.1097/00008571-200204000-00010 · Cited by 686
Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle
Jordan, A., Hadfield, J. A., Lawrence, N. J., & McGown, A. T. (1998) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199807)18:4<259::aid-med3>3.0.co;2-u · Cited by 673
Role of CYP2E1 in the Hepatotoxicity of Acetaminophen
Lee, S. S. T., Buters, J. T. M., Pineau, T., Fernandez-Salguero, P., & Gonzalez, F. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.20.12063 · Cited by 656
Stoilov, I. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.4.641 · Cited by 647
Surh, Y.-J. (1999) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s1383-5742(99)00057-5 · Cited by 633
Ross, D., Kepa, J. K., Winski, S. L., Beall, H. D., Anwar, A., & Siegel, D. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(00)00199-x · Cited by 621
Interaction of citrus juices with felodipine and nifedipine
Bailey, D., Spence, J., Munoz, C., & Arnold, J. M. O. (1991) · The Lancet · doi:10.1016/0140-6736(91)90872-m · Cited by 596
The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly Women
Felson, D. T., Zhang, Y., Hannan, M. T., Kiel, D. P., Wilson, P., & Anderson, J. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310143291601 · Cited by 585
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
Bertilsson, L., Dahl, M., Dalén, P., & Al‐Shurbaji, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01548.x · Cited by 579
Dumontet, C., & Sikic, B. I. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.1061 · Cited by 574
Weinshilboum, R. M., Otterness, D. M., & Szumlanski, C. L. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.19 · Cited by 549
A Drug over the Millennia : Pharmacognosy, Chemistry, and Pharmacology of Licorice
SHIBATA, S. (2000) · YAKUGAKU ZASSHI · doi:10.1248/yakushi1947.120.10_849 · Cited by 523
Hein, D. W. (2002) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(02)00153-7 · Cited by 518 · cited 4×
“Polymorphism is also common for may Phase II enzymes including UGTs (Mackenzie et al., 2000), SULTs (Glatt, 2000; Glatt et al., 2000, 2001), NATs (Hein, 2002), GTSs (Strange et al., 2001), and methyl transferases such as catechol-Omethyltransferase, thiopurine methyltransferase, and histamine…”
BackgroundInfluentialGender Effects in Pharmacokinetics and Pharmacodynamics
Harris, R. Z., Benet, L. Z., & Schwartz, J. B. (1995) · Drugs · doi:10.2165/00003495-199550020-00003 · Cited by 506
Aristolochic acid as a probable human cancer hazard in herbal remedies: a review
Arlt, V. M. (2002) · Mutagenesis · doi:10.1093/mutage/17.4.265 · Cited by 505
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., & Ratain, M. J. (1994) · PubMed · Cited by 501
Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro.
Potter, W. Z., Davis, D. C., Mitchell, J. R., Jollow, D. J., Gillette, J. R., & Brodie, B. B. (1973) · PubMed · Cited by 501
Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
Parman, T., Wiley, M. J., & Wells, P. G. (1999) · Nature Medicine · doi:10.1038/8466 · Cited by 495
Schuetz, E. G., Beck, W. T., & Schuetz, J. D. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08713-9 · Cited by 494
Fujiwara, T., Yoshioka, S., Yoshioka, T., Ushiyama, I., & Horikoshi, H. (1988) · Diabetes · doi:10.2337/diab.37.11.1549 · Cited by 473
Glutathione in Defense and Signaling: Lessons from a Small Thiol
DICKINSON, D. A., & FORMAN, H. J. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04690.x · Cited by 468
The importance of drug interactions in epilepsy therapy
Patsalos, P. N., Fröscher, W., Pisani, F., & Van Rijn, C. M. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.13001.x · Cited by 455
Pattern of Malformations in the Children of Women Treated with Carbamazepine during Pregnancy
Jones, K. L., Lacro, R. V., Johnson, K. A., & Adams, J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906223202505 · Cited by 447
Hepatic Dysfunction Associated with Troglitazone
Watkins, P. B., & Whitcomb, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381314 · Cited by 446
Dapsone and sulfones in dermatology: Overview and update
Zhu, Y. I., & Stiller, M. J. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.114733 · Cited by 441
Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization
KENYON, B. M., BROWNE, F., & D'AMATO, R. J. (1997) · Experimental Eye Research · doi:10.1006/exer.1997.0292 · Cited by 440
Extrahepatic Metabolism of Drugs in Humans
Krishna, D. R., & Klotz, U. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199426020-00007 · Cited by 437
Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Lai, S.-L., Yang, S.-Y., Chang, F.-Y., & Lee, S.-D. (2002) · Hepatology · doi:10.1053/jhep.2002.32102 · Cited by 432
Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
Williams, D., & Feely, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00003 · Cited by 423
Kempf, D. J., Marsh, K. C., Kumar, G., Rodrigues, A. D., Denissen, J. F., McDonald, E., Kukulka, M. J., Hsu, A., Granneman, G. R., Baroldi, P. A., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.654 · Cited by 417
Pharmacogenomics: The Inherited Basis for Interindividual Differences in Drug Response
Evans, W. E., & Johnson, J. A. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.9 · Cited by 415
Langguth, H. S., & Benet, L. Z. (1992) · Drug Metabolism Reviews · doi:10.3109/03602539208996289 · Cited by 407
Interactions of Herbs with Cytochrome P450
Zhou, S., Gao, Y., Jiang, W., Huang, M., Xu, A., & Paxton, J. W. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120018248 · Cited by 397
Self-citationDopamine turnover and glutathione oxidation: implications for Parkinson disease.
Spina, M. B., & Cohen, G. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.4.1398 · Cited by 395
Woosley, R. L., Drayer, D. E., Reidenberg, M. M., Nies, A. S., Carr, K., & Oates, J. A. (1978) · New England Journal of Medicine · doi:10.1056/nejm197805252982101 · Cited by 389
Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions
Ritter, J. K. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(00)00198-8 · Cited by 386
Sattler, M., Guengerich, F. P., Yun, C. H., Christians, U., & Sewing, K. F. (1992) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08793-8 · Cited by 385
Heel, R. C., Morley, P. A., Brogden, R. N., Carmine, A. A., Speight, T. M., & Avery, G. S. (1982) · Drugs · doi:10.2165/00003495-198224030-00001 · Cited by 384
Daluge, S. M., Good, S. S., Faletto, M. B., Miller, W. H., St Clair, M. H., Boone, L. R., Tisdale, M., Parry, N. R., Reardon, J. E., Dornsife, R. E., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1082 · Cited by 384
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Lenz, W., Pfeiffer, R. A., Kosenow, W., & Hayman, D. J. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92665-x · Cited by 379
Clustering of Hepatotoxins Based on Mechanism of Toxicity Using Gene Expression Profiles
Waring, J. F., Jolly, R. A., Ciurlionis, R., Lum, P. Y., Praestgaard, J. T., Morfitt, D. C., Buratto, B., Roberts, C., Schadt, E., & Ulrich, R. G. (2001) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2001.9243 · Cited by 376
The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*†
Fisher, M. B., Paine, M. F., Strelevitz, T. J., & Wrighton, S. A. (2001) · Drug Metabolism Reviews · doi:10.1081/dmr-120000653 · Cited by 375
Spencer, J. P. E., Jenner, P., Daniel, S. E., Lees, A. J., Marsden, D. C., & Halliwell, B. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71052112.x · Cited by 373 · cited 1×
“The resultant semiquinones/ quinones can also form conjugates with thiol compounds such as GSH and cysteine (Spencer et al., 1998).”
BackgroundBiological Properties of Olive Oil Phytochemicals
Visioli, F., & Galli, C. (2002) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408690290825529 · Cited by 369
Nolan, C. M., Goldberg, S. V., & Buskin, S. E. (1999) · JAMA · doi:10.1001/jama.281.11.1014 · Cited by 368
Sampaio, E. P., Kaplan, G., Miranda, A., Nery, J. A. C., Miguel, C. P., Viana, S. M., & Sarno, E. N. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/168.2.408 · Cited by 366
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365
Pharmacokinetic Drug Interactions of Macrolides
Periti, P., Mazzei, T., Mini, E., & Novelli, A. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223020-00004 · Cited by 358
Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation
MANYIKE, P., KHARASCH, E., KALHORN, T., & SLATTERY, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.104736 · Cited by 355
Sulfotransferases in the bioactivation of xenobiotics
Glatt, H. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(00)00202-7 · Cited by 354
Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
Humerickhouse, R. A., Lohrbach, K., Li, L., BOSRON, W. F., & Dolan, M. E. (2000) · PubMed · Cited by 353
Kumar, G. N., Rodrigues, A. D., Buko, A. M., & Denissen, J. F. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12840-1 · Cited by 353
Mechanism of Action of Acetaminophen: Is There a Cyclooxygenase 3?
Botting, R. M. (2000) · Clinical Infectious Diseases · doi:10.1086/317520 · Cited by 350
Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease
Pearce, R. K. B., Owen, A., Daniel, S., Jenner, P., & Marsden, C. D. (1997) · Journal of Neural Transmission · doi:10.1007/bf01291884 · Cited by 350
Deleu, D., Northway, M. G., & Hanssens, Y. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241040-00003 · Cited by 349
Hollenberg, P. F., Edwards, D. J., He, K., Fitzsimmons, M. E., Fisher, J. M., Rahman, A., Thummel, K. E., Lown, K. S., Woster, P. M., Schmiedlin‐Ren, P., et al. (2019) · PubMed · doi:10.17615/k2j5-jx75 · Cited by 349
Disposition of intravenous and oral cyclosporine after administration with grapefruit juice*
Ducharme, M. P., Warbasse, L. H., & Edwards, D. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90032-2 · Cited by 347
Tamoxifen for Prevention of Breast Cancer
Cersosimo, R. J. (2003) · Annals of Pharmacotherapy · doi:10.1177/106002800303700219 · Cited by 343
Enzymatic activation of chemicals to toxic metabolites
Guengerich, F. P., Liebler, D. C., & Reed, D. L. (1985) · CRC Critical Reviews in Toxicology · doi:10.3109/10408448509037460 · Cited by 334
Protein adducts: quantitative and qualitative aspects of their formation, analysis and applications
Törnqvist, M., Fred, C., Haglund, J., Helleberg, H., Paulsson, B., & Rydberg, P. (2002) · Journal of Chromatography B · doi:10.1016/s1570-0232(02)00172-1 · Cited by 332
Clinically Significant Pharmacokinetic Drug Interactions with Carbamazepine: An Update
Spina, E., Pisani, F., & Perucca, E. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631030-00004 · Cited by 331
Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy
McLeod, H. L., & Evans, W. E. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.101 · Cited by 331
Figg, W. D., Dahut, W., Duray, P. H., Hamilton, M., Tompkins, A. C., Steinberg, S. M., Jones, E. C., Premkumar, A., Linehan, W. M., Floeter, M. K., et al. (2001) · PubMed · Cited by 330
The Antiplatelet Effects of Ticlopidine and Clopidogrel
Sharis, P. J., Cannon, C. P., & Loscalzo, J. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-5-199809010-00009 · Cited by 322
Beaune, P., Dansette, P. M., Mansuy, D., Kiffel, L., Finck, M., Amar, C., Leroux, J. P., & Homberg, J. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.2.551 · Cited by 320
Medina, I., Mills, J., Leoung, G., Hopewell, P. C., Lee, B., Modin, G., Benowitz, N., & Wofsy, C. B. (1990) · New England Journal of Medicine · doi:10.1056/nejm199009203231202 · Cited by 320
Capsaicin, a double-edged sword: Toxicity, metabolism, and chemopreventive potential
Surh, Y.-J., & Sup Lee, S. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00159-4 · Cited by 318
Modulation of Acetaminophen-Induced Hepatotoxicity by the Xenobiotic Receptor CAR
Zhang, J., Huang, W., Chua, S. S., Wei, P., & Moore, D. D. (2002) · Science · doi:10.1126/science.1073502 · Cited by 316
Metabolic Polymorphisms and Susceptibility to Cancer
Vineis, P. (1999) · Cited by 313
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
He, K., Iyer, K. R., Hayes, R. N., Sinz, M., Woolf, T. F., & Hollenberg, P. F. (1998) · Chemical Research in Toxicology · doi:10.1021/tx970192k · Cited by 312
Hepatotoxicity of herbal remedies.
MacGregor, F. B., Abernethy, V. E., Dahabra, S., Cobden, I., & Hayes, P. C. (1989) · BMJ · doi:10.1136/bmj.299.6708.1156 · Cited by 311
Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., & Baillie, T. A. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000180q · Cited by 311
Ellison, D. (1966) · The Lancet · doi:10.1016/s0140-6736(66)92099-x · Cited by 308
Hanna, I. H., Dawling, S., Roodi, N., Guengerich, F. P., & Parl, F. F. (2000) · PubMed · Cited by 306
Potter, W. Z., Thorgeirsson, S. S., Jollow, D. J., & Mitchell, J. R. (1974) · Pharmacology · doi:10.1159/000136531 · Cited by 305
Selective Protein Covalent Binding and Target Organ Toxicity
Cohen, S. D., Pumford, N. R., Khairallah, E. A., Boekelheide, K., Pohl, L. R., Amouzadeh, H. R., & Hinson, J. A. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.8074 · Cited by 302
Wormhoudt, L. W., Commandeur, J. N. M., & Vermeulen, N. P. E. (1999) · Critical Reviews in Toxicology · doi:10.1080/10408449991349186 · Cited by 302
Court, M. H., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Patten, C. J., Miners, J. O., & Mackenzie, P. I. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29222-3 · Cited by 301
Drug–Grapefruit Juice Interactions
Kane, G. C., & Lipsky, J. J. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.9.933 · Cited by 301
Rolan, P. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04251.x · Cited by 301
Mitchell, J. R., Thorgeirsson, U. P., Black, M., Timbrell, J. A., Snodgrass, W. R., Potter, W. Z., Jollow, D. J., & Keiser, H. R. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518170 · Cited by 300
Faed, E. M. (1984) · Drug Metabolism Reviews · doi:10.3109/03602538409033562 · Cited by 299
Qiu, Y., Benet, L. Z., & Burlingame, A. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.28.17940 · Cited by 298
Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent
Bauer, K. S., Dixon, S. C., & Figg, W. D. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00046-x · Cited by 295
Neutropenia and Agranulocytosis in Patients Receiving Clozapine in the UK and Ireland
Atkin, K., Kendall, F., Gould, D., Freeman, H., Lieberman, J., & O'Sullivan, D. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.4.483 · Cited by 293
Mayhew, B. S., Jones, D. R., & Hall, S. D. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15182-3 · Cited by 293
Pharmacokinetics of Haloperidol
Froemming, J. S., Lam, Y. W. F., Jann, M. W., & Davis, C. M. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198917060-00004 · Cited by 291
Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies
Olyaei, A. J., de Mattos, A. M., & Bennett, W. M. (2001) · Current Opinion in Critical Care · doi:10.1097/00075198-200112000-00003 · Cited by 291
Mazzarella, R. A., & Green, M. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47496-0 · Cited by 290
Lessons from the glitazones: a story of drug development
Gale, E. A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04960-6 · Cited by 287
Aristolochic Acid and ???Chinese Herbs Nephropathy???: A Review of the Evidence to Date
Cosyns, J.-P. (2003) · Drug Safety · doi:10.2165/00002018-200326010-00004 · Cited by 286
Valproic Acid Toxicity: Overview and Management
Sztajnkrycer, M. D. (2002) · Journal of Toxicology: Clinical Toxicology · doi:10.1081/clt-120014645 · Cited by 286
Vergani, D., Mieli-Vergani, G., Alberti, A., Neuberger, J., Eddleston, A. L. W. F., Davis, M., & Williams, R. (1980) · New England Journal of Medicine · doi:10.1056/nejm198007103030202 · Cited by 285
Systematic review of amodiaquine treatment in uncomplicated malaria
Olliaro, P., Nevill, C., LeBras, J., Ringwald, P., Mussano, P., Garner, P., & Brasseur, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)06217-4 · Cited by 283
Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene
Guengerich, F. P. (1990) · Chemical Research in Toxicology · doi:10.1021/tx00016a015 · Cited by 279
Takeda, M., Khamdang, S., Narikawa, S., Kimura, H., Kobayashi, Y., Yamamoto, T., Cha, S. H., Sekine, T., & Endou, H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.918 · Cited by 276
Schmeiser, H. H., Bieler, C. A., Wießler, M., de Strihou, C. V. Y., & Cosyns, J. P. (1996) · PubMed · Cited by 272
Adverse effects of herbal drugs in dermatology
Ernst, E. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03822.x · Cited by 272
Larrey, D., Vial, T., Pauwels, A., Castot, A., Biour, M., David, M., & Michel, H. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-2-129 · Cited by 271
Yuan, R., Flockhart, D. A., & Balian, J. D. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/009127009903901102 · Cited by 271
Darke, P. L., Nutt, R. F., Brady, S. F., Garsky, V. M., Ciccarone, T. M., Leu, C.-T., Lumma, P. K., Freidinger, R. M., Veber, D. F., & Sigal, I. S. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(88)80839-8 · Cited by 268
Metabolism and bioactivation of clozapine by human liver in vitro.
Pirmohamed, M., Williams, D., Madden, S., Templeton, E., & Park, B. K. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24566-9 · Cited by 268
Evaluation of genetic risks of alkylating agents. II. Haemoglobin as a dose monitor
Osterman-Golkar, S., Ehrenberg, L., Segerbäck, D., & Hällström, I. (1976) · Mutation Research · doi:10.1016/0027-5107(76)90256-6 · Cited by 261
Human acetyltransferase polymorphisms
Grant, D. M., Hughes, N. C., Janezic, S. A., Goodfellow, G. H., Chen, H. J., Gaedigk, A., Yu, V. L., & Grewal, R. (1997) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(97)00026-2 · Cited by 261
Drug-Induced Liver Disorders: Implications for Drug Development and Regulation
Kaplowitz, N. (2001) · Drug Safety · doi:10.2165/00002018-200124070-00001 · Cited by 260
Anderson, I. B., Mullen, W. H., Meeker, J. E., Khojasteh-Bakht, S. C., Oishi, S., Nelson, S. D., & Blanc, P. D. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-8-199604150-00004 · Cited by 260
Mechanism of action in thalidomide teratogenesis
Stephens, T. D., Bunde, C. J. W., & Fillmore, B. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00388-3 · Cited by 259
Koudriakova, T., Iatsimirskaia, E., Utkin, I., Gangl, E. T., Vouros, P., Storozhuk, E., Orza, D., Marinina, J., & Gerber, N. (1998) · PubMed · Cited by 259
O'Brien, P. J. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(00)00201-5 · Cited by 258
Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4
Bargetzi, M. J., Aoyama, T., Gonzalez, F. J., & Meyer, U. A. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.180 · Cited by 257
Barry, M., Gibbons, S., Back, D., & Mulcahy, F. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00003 · Cited by 254
Mazzarella, R. A., Srinivasan, M., Haugejorden, S. M., & Green, M. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)40163-4 · Cited by 254
Oxidative damage in chemical teratogenesis
Wells, P. G., Kim, P. M., Laposa, R. R., Nicol, C. J., Parmana, T., & Winn, L. M. (1997) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(97)00175-9 · Cited by 253
Ohno, M., Yamaguchi, I., Yamamoto, I., Fukuda, T., Yokota, S., Maekura, R., Ito, M., Yamamoto, Y., Ogura, T., Maeda, K., et al. (2000) · PubMed · Cited by 251
Eriksson, T., Bjöurkman, S., Roth, B., Fyge, Å., & Höuglund, P. (1995) · Chirality · doi:10.1002/chir.530070109 · Cited by 251
Kesterson, J. W., Granneman, R. G., & Machinist, J. M. (1984) · Hepatology · doi:10.1002/hep.1840040609 · Cited by 250
Cytochrome P-450—Catalyzed Formation of Δ4-VPA, a Toxic Metabolite of Valproic Acid
Rettie, A. E., Rettenmeier, A. W., Howald, W. N., & Baillie, T. A. (1987) · Science · doi:10.1126/science.3101178 · Cited by 250
Fulton, B., & Goa, K. L. (1997) · Drugs · doi:10.2165/00003495-199753020-00007 · Cited by 250
Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir
von Moltke, L. L., Greenblatt, D. J., Grassi, J. M., Granda, B. W., Duan, S. X., Fogelman, S. M., Daily, J. P., Harmatz, J. S., & Shader, R. I. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04398.x · Cited by 248
Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects
Glatt, H., Boeing, H., Engelke, C. E. H., Ma, L., Kuhlow, A., Pabel, U., Pomplun, D., Teubner, W., & Meinl, W. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00207-x · Cited by 245
Clissold, S. P. (1986) · Drugs · doi:10.2165/00003495-198600324-00005 · Cited by 244
Pharmacokinetics of Haloperidol: An Update
Kudo, S., & Ishizaki, T. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937060-00001 · Cited by 243
Crewe, H. K., Notley, L. M., Wunsch, R. M., Lennard, M. S., & Gillam, E. M. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.869 · Cited by 241
Katayama, H., Nagasu, T., & Oda, Y. (2001) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.379 · Cited by 240
Lohr, J. W., Willsky, G. R., & Acara, M. A. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01351-6 · Cited by 237
Transformation of Lupus-Inducing Drugs to Cytotoxic Products by Activated Neutrophils
Jiang, X., Khursigara, G., & Rubin, R. L. (1994) · Science · doi:10.1126/science.7973636 · Cited by 235
BiP (GRP78), an essential hsp70 resident protein in the endoplasmic reticulum
Haas, I. G. (1994) · Experientia · doi:10.1007/bf01923455 · Cited by 234
Paracetamol: Past, Present, and Future
Prescott, L. F. (2000) · American Journal of Therapeutics · doi:10.1097/00045391-200007020-00011 · Cited by 233
Clinical Pharmacokinetics of Probenecid
Cunningham, R. F., Israili, Z. H., & Dayton, P. G. (1981) · Clinical Pharmacokinetics · doi:10.2165/00003088-198106020-00004 · Cited by 232
Carbamazepine Side Effects in Children and Adults
Pellock, J. M. (1987) · Epilepsia · doi:10.1111/j.1528-1157.1987.tb05780.x · Cited by 232
Pascussi, J.-M., Gerbal-Chaloin, S., Pichard-Garcia, L., Daujat, M., Fabre, J.-M., Maurel, P., & Vilarem, M.-J. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3219 · Cited by 231
Tamoxifen (‘Nolvadex’): a review
Clemons, M., Danson, S., & Howell, A. (2002) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(02)00036-1 · Cited by 229
Rivory, L. P., Bowles, M. R., Robert, J., & Pond, S. M. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00457-1 · Cited by 228
l‐DOPA Cytotoxicity to PC12 Cells in Culture Is via Its Autoxidation
Basma, A. N., Morris, E. J., Nicklas, W. J., & Geller, H. M. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020825.x · Cited by 226
Glutathione conjugation as a bioactivation reaction
van Bladeren, P. J. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(00)00214-3 · Cited by 226
Isoniazid and Iproniazid: Activation of Metabolites to Toxic Intermediates in Man and Rat
Nelson, S. D., Mitchell, J. R., Timbrell, J. A., Snodgrass, W. R., & Corcoran, G. B. (1976) · Science · doi:10.1126/science.7838 · Cited by 226
Jin, C., Miners, J. O., Lillywhite, K. J., & Mackenzie, P. I. (1993) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10294-2 · Cited by 226
Crewe, H. K., Ellis, S. W., Lennard, M. S., & Tucker, G. T. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00650-8 · Cited by 223
Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S -transferase Pi
Henderson, C. J., Wolf, C. R., Kitteringham, N., Powell, H., Otto, D., & Park, B. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220176997 · Cited by 222
Evidence for the involvement of N-ACETYL-p-quinoneimine in acetaminophen metabolism
Miner, D. J., & Kissinger, P. T. (1979) · Biochemical Pharmacology · doi:10.1016/0006-2952(79)90123-0 · Cited by 221
Fitzsimmons, M. E., & Collins, J. M. (1997) · PubMed · Cited by 221
Carcinogen macromolecular adducts and their measurement
Poirier, M. C., Santella, R. M., & Weston, A. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.353 · Cited by 220
GENETIC PREDISPOSITION TO PHENYTOIN-INDUCED BIRTH DEFECTS
Strickler, S., Miller, M., Andermann, E., Dansky, L., Seni, M.-H., & Spielberg, S. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90629-4 · Cited by 219
Unsafe and potentially safe herbal therapies
Klepser, T. B., & Klepser, M. E. (1999) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/56.2.125 · Cited by 217
Chitturi, S., & George, J. (2002) · Seminars in Liver Disease · doi:10.1055/s-2002-30102 · Cited by 216 · cited 1×
“…ta th io n e; N A C , N -a ce ty lL -c y te in e; G S T , g lu ta th io n eS -t ra n sf er as e. e S L E , S y te m ic lu p u s er y th em at o su s. drug-protein adduct formation and degradation, affected proteins and organs, and pathological conditions of the patients (Chitturi and George, 2002).”
BackgroundHistorical perspective on garlic and cardiovascular disease
Rahman, K. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.3.977s · Cited by 215 · cited 1×
“Organosulfur compounds in garlic are believed responsible for its beneficial biological effects, including hypolipidemic, antiplatelet, immune-enhancing, anticancer, chemopreventive, hepatoprotective, antihypertension, and procirculatory effects (Rahman, 2001; Spigelski and Jones, 2001).”
BackgroundPharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450–metabolized drugs
Rogers, J. F., Nafziger, A. N., & Bertino, J. S. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01363-3 · Cited by 215
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Santos, A., Zanetta, S., Cresteil, T., Deroussent, A., Pein, F. J. L., Raymond, É., Vernillet, L., Risse, M., Boige, V., Gouyette, A., et al. (2000) · PubMed · Cited by 213
Macrolide Antibacterials: Drug Interactions of Clinical Significance
von Rosenstiel, N.-A., & Adam, D. (1995) · Drug Safety · doi:10.2165/00002018-199513020-00005 · Cited by 212
Estrogen Receptors: How Do They Control Reproductive and Nonreproductive Functions?
Muramatsu, M., & Inoue, S. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2214 · Cited by 212
Chili Pepper Consumption and Gastric Cancer in Mexico: A Case-Control Study
López-Carnllo, L., Avila, M. H., & Dubrow, R. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116993 · Cited by 211
Hartmann, G., Cheung, A. K. Y., & Piquette-Miller, M. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039404 · Cited by 210
Boutaud, O., Aronoff, D. M., Richardson, J. H., Marnett, L. J., & Oates, J. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102588199 · Cited by 209 · cited 1×
“The mechanism of analgesic action has yet to be elucidated, but it may be due to inhibition of prostaglandin synthesis by inhibiting COX1/2 both centrally and peripherally (Botting, 2000a][b; Boutaud et al., 2002; Brune, 1986; Greco et al., 2003; Sciulli et al., 2003).”
BackgroundKenna, J. G., Satoh, H., Christ, D. D., & Pohl, L. R. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24104-0 · Cited by 209
Catecholamine toxicity in cerebral cortex in dissociated cell culture
Rosenberg, P. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-08-02887.1988 · Cited by 208
Cited by
Bruderer, R., Bernhardt, O. M., Gandhi, T., Miladinović, S. M., Cheng, L.-Y., Messner, S., Ehrenberger, T., Zanotelli, V., Butscheid, Y., Escher, C., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.044305 · Cited by 1,238
Tiwari, B., Sellamuthu, B., Ouarda, Y., Drogui, P., Tyagi, R. D., & Buelna, G. (2017) · Bioresource Technology · doi:10.1016/j.biortech.2016.11.042 · Cited by 817
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Apparent activity in high-throughput screening: origins of compound-dependent assay interference
Thorne, N., Auld, D. S., & Inglese, J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.020 · Cited by 430
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
Metadata
- Authors
- Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z.
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2005-01
- Volume
- 37
- Issue
- 1
- Pages
- 41-213
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W1997486990
- Cited by
- 274
- References
- 774
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.